Laboratory of Bioinformatics and Computational Biology, Division of Experimental and Translational Research, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil; Program of Immunology and Tumor Biology, Division of Experimental and Translational Research, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.
Laboratory of Bioinformatics and Computational Biology, Division of Experimental and Translational Research, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil; Faculdade de Biomedicina, Universidade Veiga de Almeida, Rio de Janeiro, Brazil; Laboratory for Thymus Research (LPT), Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
Infect Genet Evol. 2022 Apr;99:105236. doi: 10.1016/j.meegid.2022.105236. Epub 2022 Feb 8.
SARS-CoV-2 variants of concern have emerged since the COVID-19 outburst, notably the lineages detected in the UK, South Africa, and Brazil. Their increased transmissibility and higher viral load put them in the spotlight. Much has been investigated on the ability of those new variants to evade antibody recognition. However, little attention has been given to pre-existing and induced SARS-CoV-2-specific CD8+ T cell responses by new lineages. In this work, we predicted SARS-CoV-2-specific CD8+ T cell epitopes from the main variants of concern and their potential to trigger or hinder CD8+ T cell response by using HLA binding and TCR reactivity in silico predictions. Also, we estimated the population's coverage for different lineages, which accounts for the ability to present a set of peptides based on the most frequent HLA alleles of a given population. We considered binding predictions to 110 ccClass I HLA alleles from 29 countries to investigate differences in the fraction of individuals expected to respond to a given epitope set from new and previous lineages. We observed a higher population coverage for the variant detected in the UK (B.1.1.7), and South Africa (B.1.351), as well as for the Brazilian P.1 lineage, but not P.2, compared to the reference lineage. Moreover, individual mutations such as Spike N501Y and Nucleocapsid D138Y were predicted to have an overall stronger affinity through HLA-I than the reference sequence while Spike E484K shows signs of evasion. In summary, we provided evidence for the existence of potentially immunogenic and conserved epitopes across new SARS-CoV-2 variants, but also mutant peptides exhibiting diminished or abolished HLA-I binding. It also highlights the augmented population coverage for three new lineages. Whether these changes imply more T cell reactivity or potential to evade from CD8+ T cell responses requires experimental verification.
自 COVID-19 爆发以来,已经出现了令人关注的 SARS-CoV-2 变体,特别是在英国、南非和巴西检测到的谱系。它们的传染性增加和更高的病毒载量使它们成为焦点。人们对这些新变体逃避抗体识别的能力进行了大量研究。然而,对于新谱系引起的预先存在和诱导的 SARS-CoV-2 特异性 CD8+ T 细胞反应,关注甚少。在这项工作中,我们使用 HLA 结合和 TCR 反应性的计算机预测,从主要关注的变体及其潜在的触发或阻碍 CD8+ T 细胞反应的能力,预测了 SARS-CoV-2 特异性 CD8+ T 细胞表位。此外,我们还估计了不同谱系的人群覆盖率,这反映了根据特定人群中最常见的 HLA 等位基因呈现一组肽的能力。我们考虑了对来自 29 个国家的 110 个 ccClass I HLA 等位基因的结合预测,以研究新的和以前的谱系中的一组给定表位的预期个体反应的比例。我们观察到在英国(B.1.1.7)和南非(B.1.351)检测到的变体,以及巴西的 P.1 谱系的人群覆盖率更高,但与参考谱系相比,P.2 则不然。此外,与参考序列相比,Spike N501Y 和 Nucleocapsid D138Y 等个别突变被预测通过 HLA-I 具有更强的总体亲和力,而 Spike E484K 则显示出逃避的迹象。总之,我们提供了证据表明,新的 SARS-CoV-2 变体存在潜在的免疫原性和保守表位,但也存在降低或消除 HLA-I 结合的突变肽。它还突出了三个新谱系的更大人群覆盖率。这些变化是否意味着更多的 T 细胞反应或逃避 CD8+ T 细胞反应的潜力,需要实验验证。